GT
PTGX icon

Glenmede Trust’s Protagonist Therapeutics PTGX Stock Holding History

Glenmede Trust’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$973K Sell
9,235
-3,520
-28% -$312K ﹤0.01% 749
2025
Q4 		$1.11M Buy
+12,755
New +$1.04M 0.01% 704
2025
Q1 		$999K Buy
20,666
+11,713
+131% +$491K 0.01% 699
2024
Q4 		$346K Sell
8,953
-6,028
-40% -$263K ﹤0.01% 1047
2024
Q3 		$674K Sell
14,981
-525
-3% -$21.2K ﹤0.01% 837
2024
Q2 		$537K Buy
15,506
+4,055
+35% +$119K ﹤0.01% 882
2024
Q1 		$331K Buy
+11,451
New +$312K ﹤0.01% 1029

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Glenmede Trust's PTGX Position: Q1 2026 in Review

Glenmede Trust reduced its Protagonist Therapeutics (PTGX) stake by 28% in Q1 2026, selling an estimated $312K and leaving 9,235 shares worth $973K. The position accounts for ﹤0.01% of the portfolio, ranked #749.

Glenmede Trust first reported a position in PTGX in Q1 2024 and has held it in 7 quarters since. The position peaked at $1.11M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Glenmede Trust held 9,235 shares of Protagonist Therapeutics worth $973K as of Q1 2026.
  • Glenmede Trust sold 3,520 Protagonist Therapeutics shares in Q1 2026, an estimated $312K.
  • Protagonist Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2026, its #749 holding.
  • Glenmede Trust first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Glenmede Trust's Protagonist Therapeutics position peaked at $1.11M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.